GetTopicDetailResponse(id=8a11e9628eb, topicName=羅米地辛, introduction=羅米地辛, content=null, image=null, comments=3, allHits=1455, url=https://h5.medsci.cn/topic?id=79628, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=46482, tagList=[TagDto(tagId=46482, tagName=羅米地辛)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2213780, encodeId=12572213e8070, content=<a href='/topic/show?id=8a11e9628eb' target=_blank style='color:#2F92EE;'>#羅米地辛#</a> <a href='/topic/show?id=ce4111636139' target=_blank style='color:#2F92EE;'>#Ro-CHOP#</a> <a href='/topic/show?id=58231163623d' target=_blank style='color:#2F92EE;'>#TFH淋巴瘤#</a>, objectTitle=Ro-CHOP對比CHOP在初治外周T細胞淋巴瘤患者中的療效：Ro-CHOP試驗的最終分析, objectType=article, longId=828530, objectId=c7788285302f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240707/1720364064354_5579292.jpg, objectUrl=/article/show_article.do?id=c7788285302f, replyNumber=0, likeNumber=96, createdTime=2024-07-07, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c7788285302f, moduleTitle=Ro-CHOP對比CHOP在初治外周T細胞淋巴瘤患者中的療效：Ro-CHOP試驗的最終分析, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c7788285302f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2196508, encodeId=d40d2196508eb, content=<a href='/topic/show?id=305e1482998' target=_blank style='color:#2F92EE;'>#PTCL#</a> <a href='/topic/show?id=8a11e9628eb' target=_blank style='color:#2F92EE;'>#羅米地辛#</a> <a href='/topic/show?id=94fb1129e52c' target=_blank style='color:#2F92EE;'>#CHOP治療#</a>, objectTitle=【JCO】屢敗屢戰(zhàn)：羅米地辛+CHOP治療初治PTCL的III期研究陰性結果及評述, objectType=article, longId=818483, objectId=e68b8184832f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-writing.jpg, objectUrl=/article/show_article.do?id=e68b8184832f, replyNumber=0, likeNumber=90, createdTime=2024-04-01, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=e68b8184832f, moduleTitle=【JCO】屢敗屢戰(zhàn)：羅米地辛+CHOP治療初治PTCL的III期研究陰性結果及評述, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=e68b8184832f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1987853, encodeId=d69b198e853dc, content=<a href='/topic/show?id=8a11e9628eb' target=_blank style='color:#2F92EE;'>#羅米地辛#</a>, objectTitle=J Clin Oncol：CHOP方案加用羅米地辛治療復發(fā)/難治性外周T細胞淋巴瘤的療效和安全性, objectType=article, longId=221472, objectId=77c32214e24c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77c32214e24c, replyNumber=0, likeNumber=131, createdTime=2022-03-04, rootId=0, userName=linlin2312, userId=d590125, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77c32214e24c, moduleTitle=J Clin Oncol：CHOP方案加用羅米地辛治療復發(fā)/難治性外周T細胞淋巴瘤的療效和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=77c32214e24c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987852, encodeId=ada1198e85233, content=<a href='/topic/show?id=8a11e9628eb' target=_blank style='color:#2F92EE;'>#羅米地辛#</a>, objectTitle=Stem Cells Int：羅米地辛通過抑制組蛋白脫乙酰酶活性促進人類間充質干細胞的成骨和成脂分化, objectType=article, longId=138622, objectId=4180138622b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4180138622b0, replyNumber=0, likeNumber=94, createdTime=2018-06-13, rootId=0, userName=linlin2312, userId=d590125, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4180138622b0, moduleTitle=Stem Cells Int：羅米地辛通過抑制組蛋白脫乙酰酶活性促進人類間充質干細胞的成骨和成脂分化, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4180138622b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987851, encodeId=6045198e8511f, content=<a href='/topic/show?id=8a11e9628eb' target=_blank style='color:#2F92EE;'>#羅米地辛#</a>, objectTitle=Blood：羅米地辛與普拉曲沙的聯合治療難治性/復發(fā)性T細胞淋巴瘤可獲得高反應率。, objectType=article, longId=120438, objectId=26471204387a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26471204387a, replyNumber=0, likeNumber=80, createdTime=2017-11-19, rootId=0, userName=linlin2312, userId=d590125, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26471204387a, moduleTitle=Blood：羅米地辛與普拉曲沙的聯合治療難治性/復發(fā)性T細胞淋巴瘤可獲得高反應率。, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=26471204387a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
